Business Context and Reporting Period
This Form 8-K Current Report from Compass Therapeutics, Inc. (NASDAQ: CMPX) covers events occurring on May 28, 2024. The filing addresses significant changes in executive leadership and the Board of Directors.
Key Financial Metrics
This filing does not contain standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on personnel changes and associated compensation arrangements.
Material Changes
- CEO Resignation: Vered Bisker-Leib, PhD, MBA, resigned as Chief Executive Officer, Principal Executive Officer, Principal Financial and Accounting Officer, and Board member effective May 28, 2024. The resignation was not due to any disagreement with the Company.
- Board Reduction: The Board of Directors size was reduced to seven members following Dr. Bisker-Leib's departure.
- CEO Appointment: Thomas Schuetz, MD, PhD, previously President of Research and Development and Vice Chair of the Board, was appointed as President, Chief Executive Officer, Principal Executive Officer, Principal Financial Officer, and Principal Accounting Officer effective immediately.
Management Commentary, Risks, and Unusual Items
Separation and Consulting Agreements
Dr. Bisker-Leib entered into a Separation Agreement and a Consulting Agreement effective May 28, 2024. Key terms include:
- Compensation: 18 months of continued base salary payments and up to 18 months of Company-reimbursed COBRA premiums.
- Consulting Role: A 15-month consulting period with annual compensation of $45,000, paid quarterly.
- Equity: Outstanding equity rights will continue to vest during the consulting period. Vested options at the end of the consulting period remain exercisable for six months thereafter.
- Covenants: The agreements include releases of claims, confidentiality, non-disclosure, cooperation, non-competition, non-solicitation, and non-disparagement provisions.
The filing notes that the press release regarding these changes is attached as Exhibit 99.1 but is not deemed "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Verify the full text of the Separation Agreement (Exhibit 10.1) and Consulting Agreement (Exhibit 10.2) for specific base salary amounts and vesting acceleration details not fully quantified in the summary.
- Review the Company's most recent 10-Q or 10-K to assess the impact of the leadership transition on ongoing clinical trials and cash burn rates.
- Confirm the status of Dr. Schuetz's prior equity holdings and any new compensation arrangements not detailed in this 8-K.
- Monitor subsequent filings for any changes to the Board composition beyond the reduction to seven members.